Dosing and uses of Naftin (naftifine)
Adult dosage forms and strengths
topical cream
- 1%
- 2%
topical geL
- 1%
- 2%
Dermatophytoses
1% cream or gel: Apply BID to the affected areas plus a 0.5-inch margin of healthy surrounding skin for 4 weeks
2% cream or gel: Apply qDay to the affected areas plus a 0.5-inch margin of healthy surrounding skin for 2 weeks
Indications
- 1% cream: Indicated for treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organism Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum
- 1% gel: Indicated for treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organism Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton Tonsurans, and Epidermophyton floccosum
- 2% cream or gel: Indicated for treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organism Trichophyton rubrum
Pediatric dosage forms and strengths
topical cream
- 2%
topical geL
- 2%
Tinea Pedis
2% cream or gel: Indicated for treatment of interdigital tinea pedis caused by the organism Trichophyton rubrum
<12 years: Safety and efficacy not established
12-17 years
- Use 2% cream or gel
- Apply cream or gel qDay to the affected areas plus a 0.5-inch margin of healthy surrounding skin for 2 weeks
Tinea Corporis & Tinea Cruris
Indicated for treatment of tinea cruris or tinea corporis caused by the organism Trichophyton rubrum
<12 years: Safety and efficacy not established
12-17 years
- Use 2% cream
- Apply cream qDay to the affected areas plus a 0.5-inch margin of healthy surrounding skin for 2 weeks
Naftin (naftifine) adverse (side) effects
1-10%
Transient burning/stinging (5-6%)
Skin tenderness (0.5-3%)
Dryness
Erythema
Pruritus
Local irritation
Rash
Warnings
Contraindications
Hypersensitivity
Cautions
Avoid use of occlusive dressings or wrappings
Keep the cream away from eyes, nose, mouth, & other mucous membranes
Reevaluate dx if no improvement after 4 wk
Pregnancy and lactation
Pregnancy category: B
Lactation: not known whether excreted in breast milk; use caution
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Naftin (naftifine)
Mechanism of action
Interferes with sterol biosynthesis by inhibiting squalene monooxygenase (squalene 2,3-epoxidase)
Absorption
3-6%
Metabolism
Liver
Elimination
Excretion: 40-60% urine; 40-60% feces
